Skip to content

The effect of the upstream promoter methylation of clock-related genes Per1 and Cry1 encoding region on the interference of blood pressure circadian rhythm on cerebral microvascular disease complicated with cognitive dysfunction

The effect of the upstream promoter methylation of clock-related genes Per1 and Cry1 encoding region on the interference of blood pressure circadian rhythm on cerebral microvascular disease complicated with cognitive dysfunction

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000041152
Enrollment
Unknown
Registered
2020-12-19
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral microvascular disease complicated with cognitive dysfunction

Interventions

Cognitive impairment group:Nil

Sponsors

Lianyungang Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The patients who received MRI scan and showed lacunar infarction (LI), lacunar infarction (lacune), white matter lesions (WML), perivascular space enlargement and cerebral microbleeds (CMB) in imaging, and met the clinical diagnostic requirements of 2014 edition of "expert consensus on the diagnosis and treatment of cerebral small vessel disease".

Exclusion criteria

Exclusion criteria: 1. Subjects with obvious blindness, deafness and speech difficulty; 2. Patients diagnosed with schizophrenia, affective disorder, organic mental disorder and mental retardation; 3. Patients with dementia syndrome in degenerative diseases (Parkinson's disease, diffuse Lewy body disease, chronic progressive chorea, progressive supranuclear paralysis, thalamic dementia, Creutzfeldt Jakob disease); 4. Patients with pseudodementia (depression, delirium, brain abscess, brain tumor, hypothyroidism, hypopituitarism, vitamin deficiency, chronic renal failure and hepatic encephalopathy, etc.); 5. Subjects with normal cognitive function who have taken cholinesterase inhibitors.

Design outcomes

Primary

MeasureTime frame
Clock-related genes Per1 and Cry1;

Countries

China

Contacts

Public ContactXiaozhu Shen

Lianyungang Second People's Hospital

499062796@qq.com+86 15895783306

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026